How did DARE's revenue and expenses trend in Q4 2024?

Dare Bioscience's financial performance in Q4 2024 was characterized by a static gross margin of 100%, a slight increase of 1.73% in the last price of its stock, and a significant negative net income of approximately -$5.51 million. The company's operating expenses were not provided, but the absence of any change in gross margin suggests that the expenses may have been stable or there was no significant impact on the margin from cost changes. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |DARE|DARE.O|Dare Bioscience|20240101-2024|Royalty Revenue|9784|186| |DARE|DARE.O|Dare Bioscience|20240101-2024|Royalty Revenue|73431|186| |DARE|DARE.O|Dare Bioscience|20240101-2024|Royalty Revenue|31740|186| |DARE|DARE.O|Dare Bioscience|20240101-2024|Royalty Revenue|9302|186| |DARE|DARE.O|Dare Bioscience|20240101-2024|Royalty Revenue|9302|186| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |DARE|DARE.O|Dare Bioscience|2024 Q1|16.004287720946504|-6755356|186| |DARE|DARE.O|Dare Bioscience|2024 Q2|247.34437526876712|1.2910656E7|186| |DARE|DARE.O|Dare Bioscience|2024 Q3|43.33718997828197|-4702501|186| |DARE|DARE.O|Dare Bioscience|2024 Q4|-8.874552600640389|-5506398|186| |code|Ticker|Name|Date|Gross Profit Margin|Gross Profit Margin YoY|market_code| |---|---|---|---|---|---|---| |DARE|DARE.O|Dare Bioscience|2024 Q1|100||186| |DARE|DARE.O|Dare Bioscience|2024 Q2|100||186| |DARE|DARE.O|Dare Bioscience|2024 Q3|100|0|186| |DARE|DARE.O|Dare Bioscience|2024 Q4|100|0|186|